BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Specifically, dual targeting of BCR-ABL oncogene with a combination of allosteric and catalytic ABL inhibitors acting at distinct sites are noncross resistant and eradicate CML tumors in preclinical models (50).